Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study

CONCLUSIONS: Clinicians must note the risk of ICI-associated myositis, especially dangerous in older patients or when combined with other issues like myocarditis or severe myasthenia gravis.PMID:38629402 | DOI:10.1080/14740338.2024.2343023

Source: Expert Opinion on Drug Safety - April 17, 2024 Category: Drugs & Pharmacology Authors: Hui Yang Zhexin Ding Zhuoling An Yong Zhao Hezhe Lu Source Type: research